A. H. Conney. Pharmacological implications of microsomal enzyme induction. Pharmacol. Rev. 19(3):317–366 (1967).
R. R. Brown, J. A. Miller, and E. C. Miller. The metabolism of methylated aminoazo dyes. IV. Dietary factors enhancing demethylation in vitro. J. Biol. Chem. 209(1):211–222 (1954).
J. Y. Park, K. A. Kim, M. H. Kang, S. L. Kim, and J. G. Shin. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin. Pharmacol. Ther. 75(3):157–162 (2004).
S. C. Mueller, J. Majcher-Peszynska, B. Uehleke et al. The extent of induction of CYP3A by St. John’s wort varies among products and is linked to hyperforin dose. Eur. J. Clin. Pharmacol. 62(1):29–36 (2006).
L. Bertilsson, B. Hojer, G. Tybring, J. Osterloh, and A. Rane. Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin. Pharmacol. Ther. 27(1):83–88 (1980).
U. S. Simonsson, B. Jansson, T. N. Hai, D. X. Huong, G. Tybring, and M. Ashton. Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin. Pharmacol. Ther. 74(1):32–43 (2003).
Multiple Prescriptions. Medical Edge Mayo Clinic; 2005.
F. J. Gonzalez. The 2006 Bernard B. Brodie award lecture. Cyp2e1. Drug Metab. Dispos. 35(1):1–8 (2007).
P. Honkakoski, T. Sueyoshi, and M. Negishi. Drug-activated nuclear receptors CAR and PXR. Ann. Med. 35(3):172–182 (2003).
P. K. Mandal. Dioxin: a review of its environmental effects and its aryl hydrocarbon receptor biology. J. Comp. Physiol. [B]. 175(4):221–230 (2005).
L. B. Moore, J. M. Maglich, D. D. McKee et al. Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol. Endocrinol. 16(5):977–986 (2002).
M. Qatanani, and D. D. Moore. CAR, the continuously advancing receptor, in drug metabolism and disease. Curr. Drug Metab. 6(4):329–339 (2005).
R. G. Tirona, and R. B. Kim. Nuclear receptors and drug disposition gene regulation. J. Pharm. Sci. 94(6):1169–1186 (2005).
H. Wang, and E. L. LeCluyse. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin. Pharmacokinet. 42(15):1331–1357 (2003).
G. Lemaire, C. Delescluse, M. Pralavorio, N. Ledirac, P. Lesca, and R. Rahmani. The role of protein tyrosine kinases in CYP1A1 induction by omeprazole and thiabendazole in rat hepatocytes. Life Sci. 74(18):2265–2278 (2004).
Z. Zhu, S. Kim, T. Chen et al. Correlation of high-throughput pregnane X receptor (PXR) transactivation and binding assays. J. Biomol. Screen. 9(6):533–540 (2004).
M. F. Yueh, M. Kawahara, and J. Raucy. High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line. Drug Metab. Dispos. 33(1):38–48 (2005).
M. Sinz, S. Kim, Z. Zhu et al. Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr. Drug Metab. 7(4):375–388 (2006).
M. F. Yueh, M. Kawahara, and J. Raucy. Cell-based high-throughput bioassays to assess induction and inhibition of CYP1A enzymes. Toxicol In Vitro. 19(2):275–287 (2005).
S. Harmsen, I. Meijerman, J. H. Beijnen, and J. H. Schellens. The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treat Rev. 33(4):369–380 (2007).
S. L. Ripp, J. B. Mills, O. A. Fahmi et al. Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab. Dispos. 34(10):1742–1748 (2006).
N. J. Hewitt, R. de Kanter, and E. LeCluyse. Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry—do they comply with FDA recommendations? Chem. Biol. Interact. 168(1):51–65 (2007).
Y. D. Gao, S. H. Olson, J. M. Balkovec et al. Attenuating pregnane X receptor (PXR) activation: a molecular modelling approach. Xenobiotica. 37(2):124–138 (2007).
S. Harper, S. Avolio, B. Pacini et al. Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase. J. Med. Chem. 48(14):4547–4557 (2005).
M. Backlund, and M. Ingelman-Sundberg. Regulation of aryl hydrocarbon receptor signal transduction by protein tyrosine kinases. Cell Signal. 17(1):39–48 (2005).
W. Hu, C. Sorrentino, M. S. Denison, K. Kolaja, and M. R. Fielden. Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro. Mol. Pharmacol. 71(6):1475–1486 (2007).
J. B. Mills, K. A. Rose, N. Sadagopan, J. Sahi, and S. M. de Morais. Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J. Pharmacol. Exp. Ther. 309(1):303–309 (2004).
J. Sahi, G. Hamilton, M. Sinz et al. Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes. Xenobiotica. 30(3):273–284 (2000).
K. Lyon, R. Faris, J. Liu et al.
Improving lot-to-lot variability and dynamic range of CYP3A4 indution in immortalized human hepatocytes (Fa2N-4 cells), Internation Society for the Study of Xenobiotics, Maui, HI, 2005.
C. Aninat, A. Piton, D. Glaise et al. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab. Dispos. 34(1):75–83 (2006).
A. Guillouzo, A. Corlu, C. Aninat, D. Glaise, F. Morel, and C. Guguen-Guillouzo. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem. Biol. Interact. 168(1):66–73 (2007).
W. M. Westerink and W. G. Schoonen. Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol In Vitro. 21:1581–1591.
M. J. Gomez-Lechon, T. Donato, R. Jover et al. Expression and induction of a large set of drug-metabolizing enzymes by the highly differentiated human hepatoma cell line BC2. Eur. J. Biochem. 268(5):1448–1459 (2001).
E. L. LeCluyse, E. Alexandre, G. A. Hamilton et al. Isolation and culture of primary human hepatocytes. Methods Mol. Biol. 290:207–229 (2005).
N. J. Hewitt, M. J. Lechon, J. B. Houston et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab. Rev. 39(1):159–234 (2007).
FDA. Guidance for industry. Drug interaction studies—study design, data analysis, and implications for dosing and labeling. Draft Guidance. 2006.
E. LeCluyse, A. Madan, G. Hamilton, K. Carroll, R. DeHaan, and A. Parkinson. Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J. Biochem. Mol. Toxicol. 14(4):177–188 (2000).
D. Runge, G. K. Michalopoulos, S. C. Strom, and D. M. Runge. Recent advances in human hepatocyte culture systems. Biochem. Biophys. Res. Commun. 274(1):1–3 (2000).
H. Shih, G. V. Pickwell, D. K. Guenette, B. Bilir, and L. C. Quattrochi. Species differences in hepatocyte induction of CYP1A1 and CYP1A2 by omeprazole. Hum. Exp. Toxicol. 18(2):95–105 (1999) Feb.
M. Daujat, B. Peryt, P. Lesca, G. Fourtanier, J. Domergue, and P. Maurel. Omeprazole, an inducer of human CYP1A1 and 1A2, is not a ligand for the Ah receptor. Biochem. Biophys. Res. Commun. 188(2):820–825 (1992).
K. Dilger, Z. Zheng, and U. Klotz. Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline. Br. J. Clin. Pharmacol. 48(3):438–444 (1999).
S. Kodama, C. Koike, M. Negishi, and Y. Yamamoto. Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes. Mol. Cell. Biol. 24(18):7931–7940 (2004).
J. L. Raucy. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab. Dispos. 31(5):533–539 (2003).
J. L. Raucy, J. Lasker, K. Ozaki, and V. Zoleta. Regulation of CYP2E1 by ethanol and palmitic acid and CYP4A11 by clofibrate in primary cultures of human hepatocytes. Toxicol. Sci. 79(2):233–241 (2004).
J. L. Raucy, L. Mueller, K. Duan, S. W. Allen, S. Strom, and J. M. Lasker. Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. J. Pharmacol. Exp. Ther. 302(2):475–482 (2002).
L. Schehrer, J. D. Regan, and J. Westendorf. UDS induction by an array of standard carcinogens in human and rodent hepatocytes: effect of cryopreservation. Toxicology
D. Roymans, P. Annaert, J. Van Houdt et al. Expression and induction potential of cytochromes P450 in human cryopreserved hepatocytes. Drug Metab. Dispos. 33(7):1004–1016 (2005).
B. Reinach, G. de Sousa, P. Dostert, R. Ings, J. Gugenheim, and R. Rahmani. Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes. Chem. Biol. Interact. 121(1):37–48 (1999).
M. Nishimura, T. Imai, Y. Morioka, S. Kuribayashi, T. Kamataki, and S. Naito. Effects of NO-1886 (Ibrolipim), a lipoprotein lipase-promoting agent, on gene induction of cytochrome P450s, carboxylesterases, and sulfotransferases in primary cultures of human hepatocytes. Drug Metab. Pharmacokinet. 19(6):422–429 (2004).
E. Chung, A. N. Nafziger, D. J. Kazierad, and J. S. Bertino Jr. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin. Pharmacol. Ther. 79(4):350–361 (2006).
J. C. Gorski, S. D. Hall, D. R. Jones, M. VandenBranden, and S. A. Wrighton. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 47(9):1643–1653 (1994).
T. Kronbach, D. Mathys, M. Umeno, F. J. Gonzalez, and U. A. Meyer. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 36(1):89–96 (1989).
S. Asimus, D. Elsherbiny, T. N. Hai et al. Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects. Fundam. Clin. Pharmacol. 21(3):307–316 (2007).
C. Handschin, M. Podvinec, and U. A. Meyer. In silico approaches, and in vitro and in vivo experiments to predict induction of drug metabolism. Drug News Perspect. 16(7):423–434 (2003).
G. Lemaire, C. Benod, V. Nahoum et al. Discovery of a highly active ligand of human pregnane X receptor: a case study from pharmacophore modeling and virtual screening to “in vivo” biological activity. Mol. Pharmacol. 72(3):572–581 (2007).
R. E. Watkins, G. B. Wisely, L. B. Moore et al. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science. 292(5525):2329–2333 (2001).
P. Crivori, and I. Poggesi. Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs. Eur. J. Med. Chem. 41(7):795–808 (2006).
L. Xiao, X. Cui, V. Madison, R. E. White, and K. C. Cheng. Insights from a three-dimensional model into ligand binding to constitutive active receptor. Drug Metab. Dispos. 30(9):951–956 (2002).
S. Ekins, C. Chang, S. Mani et al. Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol. Pharmacol. 72(3):592–603 (2007).
H. Wang, H. Huang, H. Li et al. Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. Clin. Cancer Res. 13(8):2488–2495 (2007).
D. C. Hay, D. Zhao, A. Ross, R. Mandalam, J. Lebkowski, and W. Cui. Direct differentiation of human embryonic stem cells to hepatocyte-like cells exhibiting functional activities. Cloning Stem Cells. 9(1):51–62 (2007).
M. Ek, T. Soderdahl, B. Kuppers-Munther et al. Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. Biochem. Pharmacol. 74(3):496–503 (2007).
M. Ruhnke, A. K. Nussler, H. Ungefroren et al. Human monocyte-derived neohepatocytes: a promising alternative to primary human hepatocytes for autologous cell therapy. Transplantation
R. E. Schwartz, J. L. Linehan, M. S. Painschab, W. S. Hu, C. M. Verfaillie, and D. S. Kaufman. Defined conditions for development of functional hepatic cells from human embryonic stem cells. Stem Cells Dev. 14(6):643–655 (2005).
L. Rambhatla, C. P. Chiu, P. Kundu, Y. Peng, and M. K. Carpenter. Generation of hepatocyte-like cells from human embryonic stem cells. Cell Transplant. 12(1):1–11 (2003).
W. Xie, J. L. Barwick, M. Downes et al. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature
C. Tateno, Y. Yoshizane, N. Saito et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am. J. Pathol. 165(3):901–912 (2004).
M. Katoh, T. Matsui, M. Nakajima et al.
In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver. Drug Metab. Dispos. 33(6):754–763 (2005).
M. Katoh, M. Watanabe, T. Tabata et al.
In vivo induction of human cytochrome P450 3A4 by rifabutin in chimeric mice with humanized liver. Xenobiotica
M. Nishimura, T. Yokoi, C. Tateno et al. Induction of human CYP1A2 and CYP3A4 in primary culture of hepatocytes from chimeric mice with humanized liver. Drug Metab. Pharmacokinet. 20(2):121–126 (2005).
B. Carr, R. Norcross, Y. Fang et al. Characterization of the rhesus monkey CYP3A64 enzyme: species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes. Drug Metab. Dispos. 34(10):1703–1712 (2006).
T. Prueksaritanont, Y. Kuo, C. Tang et al.
In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. Drug Metab. Dispos. 34(9):1546–1555 (2006).
J. Sahi, M. W. Sinz, S. Campbell et al. Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034. Chem. Biol. Interact. 159(2):156–168 (2006).
S. R. Faucette, T. Sueyoshi, C. M. Smith, M. Negishi, E. L. Lecluyse, and H. Wang. Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J. Pharmacol. Exp. Ther. 317(3):1200–1209 (2006).
C. Handschin, and U. A. Meyer. Induction of drug metabolism: the role of nuclear receptors. Pharmacol. Rev.
K. Nakata, Y. Tanaka, T. Nakano et al. Nuclear receptor-mediated transcriptional regulation in Phase I, II, and III xenobiotic metabolizing systems. Drug Metab. Pharmacokinet. 21(6):437–457 (2006).
A. Puga, A. Maier, and M. Medvedovic. The transcriptional signature of dioxin in human hepatoma HepG2 cells. Biochem. Pharmacol. 60(8):1129–1142 (2000).
S. P. Rivera, S. T. Saarikoski, and O. Hankinson. Identification of a novel dioxin-inducible cytochrome P450. Mol. Pharmacol. 61(2):255–259 (2002).
M. Runge-Morris, and T. Kocarek. Regulation of sulfotransferases by xenobiotic receptors. Curr. Drug Metab. 6(4):299–307 (2005).
J. Zhou, J. Zhang, and W. Xie. Xenobiotic nuclear receptor-mediated regulation of UDP-glucuronosyl-transferases. Curr. Drug Metab. 6(4):289–298 (2005).
G. T. Tucker, J. B. Houston, and S. M. Huang. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--toward a consensus. Pharm. Res. 18(8):1071–1080 (2001).